64 related articles for article (PubMed ID: 1659939)
1. [CA125 in non-Hodgkin's lymphoma].
Liu CJ; Tzeng CH; Liu JH; Chaou SC; Liu JM; Fan S; Hsieh RK; Liu SM; Tiu CM; Liu RS
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Nov; 48(5):382-7. PubMed ID: 1659939
[TBL] [Abstract][Full Text] [Related]
2. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
3. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
4. CA125 expression in patients with non-Hodgkin's lymphoma.
Wei G; Yuping Z; Jun W; Bing Y; Qiaohua Z
Leuk Lymphoma; 2006 Jul; 47(7):1322-6. PubMed ID: 16923563
[TBL] [Abstract][Full Text] [Related]
5. Serum CA125 and PSA concentrations in patients with lymphoma.
Wiernik PH
Clin Adv Hematol Oncol; 2008 Jul; 6(7):527-31. PubMed ID: 18654120
[TBL] [Abstract][Full Text] [Related]
6. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer].
Liu W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
8. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience.
Altintas A; Cil T; Pasa S; Danis R; Kilinc I; Ayyildiz O; Muftuoglu E
Minerva Med; 2008 Feb; 99(1):7-14. PubMed ID: 18299692
[TBL] [Abstract][Full Text] [Related]
10. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
Urquhart A; Berg R
Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
[TBL] [Abstract][Full Text] [Related]
11. CA125 and malignant lymphomas.
Sebban C; Lasne Y; Berenguer V; Archimbaud E; Devaux Y; Viala JJ
J Clin Oncol; 1991 Feb; 9(2):359-60. PubMed ID: 1988582
[No Abstract] [Full Text] [Related]
12. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
13. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
14. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels].
Usui N; Suzuki M; Takada M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun; 44(6):703-9. PubMed ID: 1506732
[TBL] [Abstract][Full Text] [Related]
15. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
[TBL] [Abstract][Full Text] [Related]
16. The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Mariani G; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(3):243-6. PubMed ID: 2778499
[TBL] [Abstract][Full Text] [Related]
17. [Radiotherapy of primary extranodal non-Hodgkin's lymphoma of the head and neck region. Results of a prospective multicenter study. Study Group NHL: early studies].
Hoederath A; Sack H; Stuschke M; Lampka E
Strahlenther Onkol; 1996 Jul; 172(7):356-66; discussion 367-8. PubMed ID: 8693402
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
[TBL] [Abstract][Full Text] [Related]
19. [Fundamental and clinical study on source of CA 125 antigen in cul-de-sac fluid and translation into systemic circulation].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):390-6. PubMed ID: 2746065
[TBL] [Abstract][Full Text] [Related]
20. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
